Rosemary Hess
Family · Moorestown, NJNPI 1518236496
Payments from drug & device makers
Across 99 payments — averaging $21.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$515
- AbbVie$256
- Amgen$176
- Servier Pharmaceuticals LLC$159
- Pharmacyclics LLC, An Abbvie Company$150
- Sanofi$90
- plus $822 from 25 others
What the payments were for
- Food & beverage$1,87787%
- Education$29113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 16 | $515 |
| AbbVie | 12 | $256 |
| Amgen | 9 | $176 |
| Servier Pharmaceuticals LLC | 4 | $159 |
| Pharmacyclics LLC, An Abbvie Company | 7 | $150 |
| Sanofi | 5 | $90 |
| E.r. Squibb & Sons, L.L.C. | 4 | $67 |
| Taiho Oncology, Inc. | 4 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Bayer | 3 | $55 |
| Pharmacosmos Therapeutics Inc. | 2 | $47 |
| Eisai Inc. | 3 | $46 |
| Merck | 2 | $40 |
| EMD Serono, Inc. | 2 | $39 |
| Daiichi Sankyo Inc. | 2 | $37 |
| Tersera Therapeutics LLC | 2 | $36 |
| GSK | 1 | $34 |
| Incyte Corporation | 2 | $32 |
| AVEO Pharmaceuticals, Inc. | 2 | $30 |
| Astellas Pharma US Inc | 2 | $29 |
| Seagen Inc. | 2 | $29 |
| Novartis | 1 | $24 |
| Genmab U.S., Inc. | 1 | $22 |
| Puma Biotechnology, Inc. | 1 | $20 |
| G1 Therapeutics, Inc. | 1 | $19 |
| Clovis Oncology, Inc. | 1 | $18 |
| Bristol Myers Squibb | 1 | $18 |
| AstraZeneca | 1 | $16 |
| Myovant Sciences Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $13 |
How this compares
$2,168 in reported general payments places this provider in the 85th percentile of 2,692 family providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 21 | $14,696 |
| EliquisApixaban | 12 | $12,822 |
| XareltoRivaroxaban | 16 | $11,919 |
| Prochlorperazine Maleate | 177 | $2,859 |
| Oxycodone Hcl | 75 | $1,420 |
| Ondansetron OdtOndansetron | 159 | $1,058 |
| Dexamethasone | 46 | $1,003 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 43 | $934 |
| Anastrozole | 26 | $931 |
| ValacyclovirValacyclovir Hcl | 18 | $634 |
| Pantoprazole Sodium | 19 | $472 |
| Potassium Chloride | 13 | $339 |
| Clotrimazole | 11 | $334 |
| Acyclovir | 29 | $290 |
| Tramadol Hcl | 39 | $257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $515 | $11,91916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,692 family providers in New Jersey.
Other family in Moorestown
- Jennifer DemaioMorristown$412K
- Kara TrlicaCranbury$186K
- Nicole BauerParamus$161K
- Angie GarciaWest New York$161K
- China BattistaWall Township$142K
- Nancy EisenbergerVoorhees$82K
- Jennifer AbitabiloGlen Ridge$54K
- Megan FiloramoMorristown$53K
- Shawn DenningToms River$29K
- Kimberly ClementeEatontown$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.